200 related articles for article (PubMed ID: 27448913)
1. New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities.
Wang P; Huang J; Wang K; Gu Y
Eur J Med Chem; 2016 Oct; 122():546-556. PubMed ID: 27448913
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anticancer activities of ceritinib analogs modified in the terminal piperidine ring.
Wang P; Cai J; Chen J; Ji M
Eur J Med Chem; 2015 Mar; 93():1-8. PubMed ID: 25644671
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.
Shan H; Ma X; Yan G; Luo M; Zhong X; Lan S; Yang J; Liu Y; Pu C; Tong Y; Li R
Eur J Med Chem; 2021 Jul; 219():113432. PubMed ID: 33857728
[TBL] [Abstract][Full Text] [Related]
4. Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation.
Ashraf Z; Mahmood T; Hassan M; Afzal S; Rafique H; Afzal K; Latip J
Drug Des Devel Ther; 2019; 13():1643-1657. PubMed ID: 31190743
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid-nucleosides analogues.
Huang LH; Xu HD; Yang ZY; Zheng YF; Liu HM
Steroids; 2014 Apr; 82():1-6. PubMed ID: 24378780
[TBL] [Abstract][Full Text] [Related]
6. Scaffold Hopping Approach to a New Series of Pyridine Derivatives as Potent Inhibitors of CDK2.
Xu X; Yao Q
Arch Pharm (Weinheim); 2016 Mar; 349(3):224-31. PubMed ID: 26871934
[TBL] [Abstract][Full Text] [Related]
7. Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo.
Elango R; Vishnubalaji R; Manikandan M; Binhamdan SI; Siyal AA; Alshawakir YA; Alfayez M; Aldahmash A; Alajez NM
Sci Rep; 2019 Sep; 9(1):13696. PubMed ID: 31548560
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib and Michael-acceptor hybrid compounds as CDK4/6 covalent inhibitors: Improved potency, broad anticancer spectrum and overcoming drug resistance.
Fang L; Chu M; Yan C; Liu Y; Zhao Z
Bioorg Med Chem; 2023 Apr; 84():117263. PubMed ID: 37011445
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
Filosa R; Peduto A; de Caprariis P; Saturnino C; Festa M; Petrella A; Pau A; Pinna GA; La Colla P; Busonera B; Loddo R
Eur J Med Chem; 2007 Mar; 42(3):293-306. PubMed ID: 17254669
[TBL] [Abstract][Full Text] [Related]
10. Novel 1-(2-aryl-2-adamantyl)piperazine derivatives with antiproliferative activity.
Fytas C; Zoidis G; Tsotinis A; Fytas G; Khan MA; Akhtar S; Rahman KM; Thurston DE
Eur J Med Chem; 2015 Mar; 93():281-90. PubMed ID: 25703296
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer activity of novel hybrid compounds between benzofuran and N-aryl piperazine.
Mao ZW; Zheng X; Lin YP; Hu CY; Wang XL; Wan CP; Rao GX
Bioorg Med Chem Lett; 2016 Aug; 26(15):3421-4. PubMed ID: 27371110
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
Toogood PL; Harvey PJ; Repine JT; Sheehan DJ; VanderWel SN; Zhou H; Keller PR; McNamara DJ; Sherry D; Zhu T; Brodfuehrer J; Choi C; Barvian MR; Fry DW
J Med Chem; 2005 Apr; 48(7):2388-406. PubMed ID: 15801831
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of pyrrolo[2,3-b]pyridine analogues as antiproliferative agents and their interaction with calf thymus DNA.
Narva S; Chitti S; Bala BR; Alvala M; Jain N; Kondapalli VG
Eur J Med Chem; 2016 May; 114():220-31. PubMed ID: 26994690
[TBL] [Abstract][Full Text] [Related]
14. Selective degradation of CDK6 by a palbociclib based PROTAC.
Rana S; Bendjennat M; Kour S; King HM; Kizhake S; Zahid M; Natarajan A
Bioorg Med Chem Lett; 2019 Jun; 29(11):1375-1379. PubMed ID: 30935795
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors.
Sun J; Ren SZ; Lu XY; Li JJ; Shen FQ; Xu C; Zhu HL
Bioorg Med Chem; 2017 May; 25(9):2593-2600. PubMed ID: 28363444
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antiproliferative effect of novel 4-thiazolidinone-, pyridine- and piperazine-based conjugates on human leukemic cells.
Sharath Kumar KS; Hanumappa A; Hegde M; Narasimhamurthy KH; Raghavan SC; Rangappa KS
Eur J Med Chem; 2014 Jun; 81():341-9. PubMed ID: 24852281
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives.
Liu Y; Zhang S; Li Y; Wang J; Song Y; Gong P
Arch Pharm (Weinheim); 2012 Apr; 345(4):287-93. PubMed ID: 22006840
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and docking studies of novel 1,2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamide derivatives as a potential anti-proliferative agents.
Banu S; Bollu R; Bantu R; Nagarapu L; Polepalli S; Jain N; Vangala R; Manga V
Eur J Med Chem; 2017 Jan; 125():400-410. PubMed ID: 27688193
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anticancer activity of novel 2-pyridyl hexahyrocyclooctathieno[2,3-d]pyrimidine derivatives.
Kassab AE; Gedawy EM
Eur J Med Chem; 2013 May; 63():224-30. PubMed ID: 23501108
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anticancer activity of N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives.
Gudisela MR; Srinivasu N; Mulakayala C; Bommu P; Rao MVB; Mulakayala N
Bioorg Med Chem Lett; 2017 Sep; 27(17):4140-4145. PubMed ID: 28756024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
